Consequently, previous clinical trials using monoclonal antibodies and tyrosine kinase inhibitors against IGF-1R have failed to demonstrate a significant benefit for cancer patients, likely due to a lack of patient selection [151,162,168]. This evidence concerns the gene IGF1R and cancer.